Related Experiment Video
Updated: Jul 19, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Innovative technologies and their clinical prospects for early lung cancer screening
Zisu Deng1,2, Xiaocao Ma3, Shubiao Zou1
1Department of Nuclear Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Background:
Lung cancer remains the leading cause of cancer-related mortality worldwide, due to lacking effective early-stage screening approaches. Imaging, such as low-dose CT, poses radiation risk, and biopsies can induce some complications. Additionally, traditional serum tumor markers lack diagnostic specificity. This highlights the urgent need for precise and non-invasive early detection techniques.
Purpose:
This systematic review aims to evaluate the limitations of conventional screening methods (imaging/biopsy/tumor markers), seek breakthroughs in liquid biopsy for early lung cancer detection, and assess the potential value of Artificial Intelligence (AI), thereby providing evidence-based insights for establishing an optimal screening framework.
Methods:
We systematically searched the PubMed database for the literature published up to May 2025. Key words include "Artificial Intelligence", "Early Lung cancer screening", "Imaging examination", "Innovative technologies", "Liquid biopsy", and "Puncture biopsy". Our inclusion criteria focused on studies about traditional and innovative screening methods, with an emphasis on original research concerning diagnostic performance or high-quality reviews. This approach helps identify critical studies in early lung cancer screening.
Conclusions:
Novel liquid biopsy techniques are non-invasive and have superior diagnostic efficacy. AI-assisted diagnostics further enhance accuracy. We propose three development directions: establishing risk-based liquid biopsy screening protocols, developing a stepwise "imaging-AI-liquid biopsy" diagnostic workflow, and creating standardized biomarker panel testing solutions. Integrating traditional methodologies, novel liquid biopsies, and AI to establish a comprehensive early lung cancer screening model is important. These innovative strategies aim to significantly increase early detection rates, substantially enhancing lung cancer control. This review provides both theoretical guidance for clinical practice and future research.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
07:53Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
Published on: October 13, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...